Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.28
24.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one QNRX stock under the Base Case scenario is 28.38 USD. Compared to the current market price of 13.9 USD, Quoin Pharmaceuticals Ltd is Undervalued by 51%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Quoin Pharmaceuticals Ltd.
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Quoin Pharmaceuticals Ltd
Balance Sheet Decomposition
Quoin Pharmaceuticals Ltd
| Current Assets | 6m |
| Cash & Short-Term Investments | 5.4m |
| Other Current Assets | 602.6k |
| Non-Current Assets | 408.4k |
| Intangibles | 408.3k |
| Other Non-Current Assets | 100 |
| Current Liabilities | 5.8m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 3.3m |
| Short-Term Debt | 600k |
| Other Current Liabilities | 100 |
| Non-Current Liabilities | 1.9m |
| Long-Term Debt | 1.9m |
Free Cash Flow Analysis
Quoin Pharmaceuticals Ltd
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Quoin Pharmaceuticals Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-14.2m
USD
|
|
Operating Income
|
-14.2m
USD
|
|
Other Expenses
|
407.8k
USD
|
|
Net Income
|
-13.8m
USD
|
QNRX Profitability Score
Profitability Due Diligence
Quoin Pharmaceuticals Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Quoin Pharmaceuticals Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
QNRX Solvency Score
Solvency Due Diligence
Quoin Pharmaceuticals Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Quoin Pharmaceuticals Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNRX Price Targets Summary
Quoin Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for QNRX is 42.5 USD with a low forecast of 25.25 USD and a high forecast of 73.5 USD.
Dividends
Current shareholder yield for QNRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one QNRX stock under the Base Case scenario is 28.38 USD.
Compared to the current market price of 13.9 USD, Quoin Pharmaceuticals Ltd is Undervalued by 51%.